Is Rubius Therapeutics Inc (RUBY) Stock at the Top of the Biotechnology Industry?

Wednesday, December 01, 2021 11:10 AM | InvestorsObserver Analysts

Mentioned in this article

Is Rubius Therapeutics Inc (RUBY) Stock at the Top of the Biotechnology Industry?

A rating of 84 puts Rubius Therapeutics Inc (RUBY) near the top of the Biotechnology industry according to InvestorsObserver. Rubius Therapeutics Inc's score of 84 means it scores higher than 84% of stocks in the industry. Rubius Therapeutics Inc also received an overall rating of 54, putting it above 54% of all stocks. Biotechnology is ranked 80 out of the 148 industries.

RUBY has an Overall Score of 54. Find out what this means to you and get the rest of the rankings on RUBY!

See Full RUBY Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 54 would rank higher than 54 percent of all stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes

InvestorsObserver

’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Rubius Therapeutics Inc Stock Today?

Rubius Therapeutics Inc (RUBY) stock has fallen -1.29% while the S&P 500 has risen 1.62% as of 11:05 AM on Wednesday, Dec 1. RUBY is lower by -$0.16 from the previous closing price of $12.36 on volume of 508,039 shares. Over the past year the S&P 500 has gained 26.72% while RUBY has risen 85.98%. RUBY lost -$2.12 per share the over the last 12 months. Click Here to get the full Stock Report for Rubius Therapeutics Inc stock.